The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Palindromic Rheumatism: Will It Progress to Severe Rheumatoid Arthritis?

Palindromic Rheumatism: Will It Progress to Severe Rheumatoid Arthritis?

October 18, 2018 • By Amaka Odonwodo, MD, MPH, & Carlos Julio Aponte, MD, FACP, FACR

  • Tweet
  • Email
Print-Friendly Version / Save PDF
BLACKDAYutterstock.com

BLACKDAYutterstock.com

Palindromic rheumatism (PR) was first described in 1944 as “unique in its nature of recurrent, transient episodes of excruciatingly painful inflammation of articular and periarticular tissues, followed by periods without symptoms.”1 Unfortunately, it is becoming evident this entity is more frequent than we thought.2

You Might Also Like
  • Progress Slow in Development of Useful Biomarkers for Rheumatoid Arthritis Treatment
  • Rheumatoid Arthritis Patients Have More Severe ACS, Poorer Outcomes
  • Arthritis & Rheumatism (A&R) Gets a New Name
Explore This Issue
October 2018

PR is easily ignored or misdiagnosed due to its character (i.e., no symptoms or signs between attacks) and because patients usually present after resolution of symptoms, with no evidence of acute inflammation on clinical, serologic or radiologic examination.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

An experienced rheumatologist obtaining a focused history usually finds it necessary to diagnose PR. In a 1987 study, Hannonen et al. proposed this diagnostic criteria: 1) recurrent attacks of sudden-onset mono- or polyarthritis, or of a peri­articular tissue inflammation, lasting from a few hours to one week; 2) verification of at least one attack by a physician; 3) subsequent attacks in at least three different joints; and 4) exclusion of other forms of arthritides.3

We have observed over the years in a large rheumatology practice the difficulty of obtaining a focused history necessary to suspect and diagnose PR, and the difficulty patients, family and referring doctors have had with accepting the diagnosis. We also noted the evolution of patients with PR to severe forms of rheumatoid arthritis (RA) was more common than expected and that these patients suffered from particularly severe RA.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Below, we describe two such cases.

Case No. 1

A 60-year-old Hispanic male presented with acute onset pain of the right wrist attributed to mild trauma. This resolved spontaneously over the course of a few hours. Pain and swelling resurfaced two weeks later, however, this time in his left elbow. Conservative measures were taken, and symptoms of pain, swelling and redness subsided within 36 hours.

Over the course of the next two months, the patient experienced intermittent episodes of abrupt onset, excruciating pain at various joints (usually one to three joints simultaneously). These episodes lasted 10–40 hours and subsided almost as abruptly as they started. Naproxen helped ease the pain.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

The patient was seen by an internist during one such flare, and lab tests, which included complete blood count (CBC), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), uric acid and thyroid stimulating hormone (TSH), were normal.

Three months later he presented to a rheumatologist with persistent pain in his right wrist and metacarpals (MCPs) associated with morning stiffness. A focused history revealed the absence of trauma (although the patient kept blaming nonexistent “possible” trauma because there was swelling and pain). Further investigation revealed a positive rheumatoid factor (RF), anti-cyclic citrullinated peptide (anti-CCP) and elevated CRP. Joint X-rays proved unremarkable. Given these more classical signs of RA, he was treated with hydroxychloroquine, methotrexate, naproxen and low-dose prednisone.

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: Classification Criteria, Palindromic RheumatismIssue: October 2018

You Might Also Like:
  • Progress Slow in Development of Useful Biomarkers for Rheumatoid Arthritis Treatment
  • Rheumatoid Arthritis Patients Have More Severe ACS, Poorer Outcomes
  • Arthritis & Rheumatism (A&R) Gets a New Name
  • Preclinical Phases of Rheumatoid Arthritis Better Understood

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)